
Shattuck Labs (STTK) Stock Forecast & Price Target
Shattuck Labs (STTK) Analyst Ratings
Bulls say
Shattuck Labs Inc. is positioned favorably in the biotechnology sector due to its innovative development of SL-325, a potential first-in-class antibody aimed at treating inflammatory bowel disease (IBD) and other immune-mediated diseases, backed by strong expertise in protein engineering. The data indicates a significant increase in biologic use among patients with Crohn's disease (CD) and ulcerative colitis (UC) from 2007 to 2015, suggesting a growing market for effective treatments, which aligns with Shattuck's focus on high-efficacy therapeutics. Furthermore, the company's conservative estimates for the sales growth of SL-325 reflect confidence in robust market share expansion driven by consistent demand for effective therapies in the face of rising biologic usage rates.
Bears say
Shattuck Labs Inc faces challenges that may adversely impact its stock outlook due to the potential ineffectiveness and risks associated with its leading candidates, SL-325 and SL-425, which might not meet safety or efficacy expectations. Furthermore, the consistent underestimation of market growth and advanced therapy usage in inflammatory bowel disease (IBD) may hinder the commercial success of the company’s treatment approaches, as they may not align with market dynamics. As increasing utilization of biologics correlates with declining surgery rates, it raises concerns about market penetration and adoption for Shattuck Labs's therapies in a competitive landscape.
This aggregate rating is based on analysts' research of Shattuck Labs and is not a guaranteed prediction by Public.com or investment advice.
Shattuck Labs (STTK) Analyst Forecast & Price Prediction
Start investing in Shattuck Labs (STTK)
Order type
Buy in
Order amount
Est. shares
0 shares